These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23360448)

  • 21. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
    Sirohi S; Aldrich JV; Walker BM
    Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.
    Browne CA; Wulf H; Lucki I
    Handb Exp Pharmacol; 2022; 271():493-524. PubMed ID: 33580854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch from excitatory to inhibitory actions of ethanol on dopamine levels after chronic exposure: Role of kappa opioid receptors.
    Karkhanis AN; Huggins KN; Rose JH; Jones SR
    Neuropharmacology; 2016 Nov; 110(Pt A):190-197. PubMed ID: 27450094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
    An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
    ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction.
    Chartoff EH; Mavrikaki M
    Front Neurosci; 2015; 9():466. PubMed ID: 26733781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related Disorders.
    Jacobson ML; Browne CA; Lucki I
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():615-636. PubMed ID: 31914893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action.
    Aldrich JV; Patkar KA; McLaughlin JP
    Proc Natl Acad Sci U S A; 2009 Oct; 106(43):18396-401. PubMed ID: 19841255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alanine scan of the opioid peptide dynorphin B amide.
    Joshi AA; Murray TF; Aldrich JV
    Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28464209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early life stress dysregulates kappa opioid receptor signaling within the lateral habenula.
    Simmons SC; Shepard RD; Gouty S; Langlois LD; Flerlage WJ; Cox BM; Nugent FS
    Neurobiol Stress; 2020 Nov; 13():100267. PubMed ID: 33344720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.
    Tejeda HA; Chefer VI; Zapata A; Shippenberg TS
    Psychopharmacology (Berl); 2010 Jun; 210(2):231-40. PubMed ID: 20232058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.
    Land BB; Bruchas MR; Lemos JC; Xu M; Melief EJ; Chavkin C
    J Neurosci; 2008 Jan; 28(2):407-14. PubMed ID: 18184783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide kappa opioid receptor ligands: potential for drug development.
    Aldrich JV; McLaughlin JP
    AAPS J; 2009 Jun; 11(2):312-22. PubMed ID: 19430912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats.
    Silva RM; Grossman HC; Hadjimarkou MM; Rossi GC; Pasternak GW; Bodnar RJ
    J Pharmacol Exp Ther; 2002 May; 301(2):513-8. PubMed ID: 11961051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
    Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
    J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments.
    Mercadante S; Romualdi P
    Curr Med Chem; 2020; 27(12):2012-2020. PubMed ID: 30666905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
    Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
    Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
    Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
    Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).
    Guerrero M; Urbano M; Kim EK; Gamo AM; Riley S; Abgaryan L; Leaf N; Van Orden LJ; Brown SJ; Xie JY; Porreca F; Cameron MD; Rosen H; Roberts E
    J Med Chem; 2019 Feb; 62(4):1761-1780. PubMed ID: 30707578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.